phrykt

Cogent Biosciences, Inc. (COGT): who owns it and who trades it

As of Nov 16, 2026, COGT insiders reported 8 open-market sales worth $384M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Fairmount Funds Management LLC (Director), with $370M. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Cogent Biosciences

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns COGT

321 funds and institutions reported COGT shares worth $7.7B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)15.0%
BlackRock, Inc.10.2%
Vanguard Portfolio Management LLC4.7%
Vanguard Capital Management LLC4.3%
State Street Corp4.1%
Jupiter Topco LLC3.9%
Fairmount Funds Management LLC3.2%
California State Teachers Retirement System3.2%
Deerfield Management Company, L.P.2.9%
TCG Crossover Management, LLC2.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)25.68M15.03%$994M+11%
BlackRock, Inc.17.35M10.16%$672M+8%
Vanguard Portfolio Management LLC8.07M4.72%$312M+10%
Vanguard Capital Management LLC7.41M4.34%$287M+8%
State Street Corp6.96M4.08%$270M+23%
Jupiter Topco LLC6.62M3.88%$256M–
Fairmount Funds Management LLC5.50M3.22%$213MNo change
California State Teachers Retirement System5.48M3.21%$142M–
Deerfield Management Company, L.P.5.01M2.93%$194M-45%
TCG Crossover Management, LLC4.85M2.84%$188M-2%
T. Rowe Price Associates4.65M2.72%$180M+45%
Geode Capital Management, LLC4.51M2.64%$175M+22%
Wellington Management Group LLP4.34M2.54%$168M+21%
Kynam Capital Management, LP3.67M2.15%$142M-9%
Lord, Abbett & Co. LLC3.43M2.01%$133M+8%
Polar Capital Holdings Plc3.23M1.89%$125M–
Commodore Capital LP3.05M1.79%$118M+6%
Assenagon Asset Management S.A.2.88M1.69%$112M+875%
Invesco Ltd.2.61M1.53%$101M+7%
Woodline Partners LP2.60M1.52%$101M+72%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, COGT insiders reported $0 of open-market purchases and $384M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$384M
8 trades, 6 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Aug 27, 2026
Filed Aug 31, 2026

Purchases and sales by month

$243M$243MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 27, 2026Arlene MorrisDirectorSale3,161$37.54$119KForm 4
Aug 27, 2026Arlene MorrisDirectorSale42,349$37.09$1.6MForm 4
Mar 31, 2026Fairmount Funds Management LLCDirectorSale7.00M$34.66$243MForm 4
Jan 22, 2026Fairmount Funds Management LLCDirectorSale3.50M$36.40$127MForm 4
Dec 26, 2025Evan KearnsChief Legal OfficerSale65,000$38.70$2.5MForm 4
Dec 26, 2025John L. GreenCFOSale77,000$38.68$3MForm 4
Dec 26, 2025Jessica SachsChief Medical OfficerSale82,642$38.70$3.2MForm 4
Dec 26, 2025John Edward RobinsonChief Scientific OfficerSale90,000$38.74$3.5MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Fairmount Funds Management LLCDirector–$370MMar 31, 2026
John Edward RobinsonChief Scientific Officer–$3.5MDec 26, 2025
Jessica SachsChief Medical Officer–$3.2MDec 26, 2025
John L. GreenChief Financial Officer–$3MDec 26, 2025
Evan KearnsChief Legal Officer–$2.5MDec 26, 2025
Arlene MorrisDirector–$1.7MAug 27, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

COGT short interest

High short interest. 10.0% of COGT shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 56%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 17.42M COGT shares were sold short, 10.0% of the shares outstanding, down 11.4% from the report before. At the average daily volume of 2.01M shares, buying them all back would take about 8.7 trading days (days to cover).

Shares short, % of all shares

10.0%May 15Oct 3012.1%

Days to cover

8.7May 15Oct 3013.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202617.42M10.04%-11%2.01M8.7
Oct 15, 202619.66M11.33%+1%2.20M8.9
Sep 30, 202619.46M11.22%+7%2.41M8.1
Sep 15, 202618.13M10.45%-3%1.53M11.8
Aug 31, 202618.75M10.80%+2%1.55M12.1
Aug 14, 202618.41M10.61%+3%2.06M8.9
Jul 31, 202617.89M10.47%+8%1.70M10.5
Jul 15, 202616.56M9.69%+1%2.47M6.7
Jun 30, 202616.35M9.57%+22%4.22M3.9
Jun 15, 202613.45M7.87%+17%2.31M5.8
May 29, 202611.52M6.74%+3%2.37M4.9
May 15, 202611.16M6.53%-5%1.49M7.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Cogent Biosciences company events

Cogent Biosciences filed 9 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 2, 2026AgreementCogent Biosciences, Inc. entered into a Commercial Supply Agreement with Hovione FarmaCiencia S.A. to manufacture bezuclastinib spray-dried dispersion and bezuclastinib tablets. Filing
  3. Aug 10, 2026AnnouncementAs previously disclosed, on May 6, 2022, Cogent Biosciences, Inc. entered into a Sales Agreement with Guggenheim Securities, LLC, as amended by that certain Amendment No. 1 to Sales Agreement, dated November 7, 2025 (as amended, the “Sales Agreement”), pursuant to which the Company may offer and… Filing
  4. Aug 10, 2026ResultsReleased financial results. Filing
  5. Jun 11, 2026VoteReported shareholder vote results. Filing
  6. May 5, 2026ResultsReleased financial results. Filing
  7. Feb 17, 2026ResultsReleased financial results. Filing
  8. Dec 8, 2025AnnouncementOn December 6, 2025 and December 8, 2025, Cogent Biosciences, Inc. presented the full results from its SUMMIT clinical trial of bezuclastinib in patients with nonadvanced systemic mastocytosis and announced positive top-line results from its APEX clinical trial of bezuclastinib in patients with… Filing
  9. Nov 18, 2025AgreementCogent Biosciences, Inc. completed its previously-announced public offering of $230 million of its 1.625% Convertible Senior Notes due 2031, including the exercise in full of the underwriters’ over-allotment option to purchase up to an additional $30.0 million principal amount of the Notes. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Cogent Biosciences financials

Famous investors that hold COGT

6 of the 50 well-known investors we track reported holding COGT in their latest 13F filing. The largest position is Ken Griffin's, worth $31.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026990,010$31.7M0.0%+17%
Steve Cohen · Point72 Asset ManagementQ3 2026790,494$25.3M0.0%+6%
Jim Simons · Renaissance TechnologiesQ3 2026708,668$22.7M0.0%-29%
Israel Englander · Millennium ManagementQ3 2026324,672$10.4M0.0%-64%
Stanley Druckenmiller · Duquesne Family OfficeQ3 2026221,112$7.1M0.2%New
Ken Fisher · Fisher Asset ManagementQ3 2026152,498$4.9M0.0%-18%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Cogent Biosciences, Inc. (COGT) stock

Who owns the most COGT stock?

The largest reported owner of Cogent Biosciences, Inc. (COGT) is FMR LLC (Fidelity), with 15.0% of the company. In total, 321 funds and institutions reported holding COGT at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are COGT insiders buying or selling?

In the last 12 months, COGT insiders reported no open-market purchases and 8 sales worth $384M. The latest trade was on Aug 27, 2026. See every trade.

What is the short interest in COGT?

As of Oct 30, 2026, 17.42M COGT shares were sold short, 10.0% of the shares outstanding, down 11.4% from the report before. At the average daily volume of 2.01M shares, buying them all back would take about 8.7 trading days (days to cover). See the history.

Which famous investors hold COGT?

6 of the 50 well-known investors we track reported COGT in their latest 13F filing, including Ken Griffin, Steve Cohen, Jim Simons. The largest position is worth $31.7M. See all holders.

Executive pay

Cogent Biosciences's chief executive was paid a total of $27.8M for the year ended Dec 31, 2025, up 465% from $4.9M the year before. In the last 12 months, Cogent Biosciences's executives and directors bought no stock on the open market and sold $13.9M.

Chief executive, total pay$27.8MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$117MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$8.9MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.